Literature DB >> 36262484

Primary Mediastinal B-cell Lymphoma Presenting as Chest Pain in a Young Woman and Treated with EPOCH-R.

Chloe Weidenbaum1,2, Akanksha Kushwah1,2, Ariana Geromes2, Jonathan A Abbas2.   

Abstract

Primary mediastinal B-cell lymphoma (PMBCL) is a rare type of diffuse large B-cell lymphoma, constituting 2-4% of non-Hodgkin lymphomas. Here we present a case of PMBCL initially presenting as pleuritic chest pain in an otherwise healthy 33-year-old woman. PMBCL typically presents as a large, fast-growing tumor limited to the mediastinum, making the iliosacral involvement in this case unusual. R-CHOP is the most commonly used chemotherapy regimen, although more aggressive therapies like EPOCH-R can spare the need for consolidative radiation therapy. PMBCL represents one of the greatest diagnostic and therapeutic challenges in malignant hematology.
© 2022 Greater Baltimore Medical Center.

Entities:  

Keywords:  Chest pain; Diffuse large B-Cell lymphoma; EPOCH-R; Non-hodgkin lymphoma; R-CHOP

Year:  2022        PMID: 36262484      PMCID: PMC9529639          DOI: 10.55729/2000-9666.1105

Source DB:  PubMed          Journal:  J Community Hosp Intern Med Perspect        ISSN: 2000-9666


  12 in total

Review 1.  How I treat primary mediastinal B-cell lymphoma.

Authors:  Lisa Giulino-Roth
Journal:  Blood       Date:  2018-07-05       Impact factor: 22.113

2.  R-CHOP versus dose-adjusted R-EPOCH in frontline management of primary mediastinal B-cell lymphoma: a multi-centre analysis.

Authors:  Nirav N Shah; Aniko Szabo; Scott F Huntington; Narendranath Epperla; Nishitha Reddy; Siddhartha Ganguly; Julie Vose; Cynthia Obiozor; Fahad Faruqi; Alexandra E Kovach; Luciano J Costa; Ana C Xavier; Ryan Okal; Abraham S Kanate; Nilanjan Ghosh; Mohamed A Kharfan-Dabaja; Lauren Strelec; Mehdi Hamadani; Timothy S Fenske; Oscar Calzada; Jonathon B Cohen; Julio Chavez; Jakub Svoboda
Journal:  Br J Haematol       Date:  2017-12-19       Impact factor: 6.998

3.  Favorable outcome of primary mediastinal large B-cell lymphoma in a single institution: the British Columbia experience.

Authors:  K J Savage; N Al-Rajhi; N Voss; C Paltiel; R Klasa; R D Gascoyne; J M Connors
Journal:  Ann Oncol       Date:  2005-10-19       Impact factor: 32.976

Review 4.  Primary mediastinal B-cell lymphoma and mediastinal gray zone lymphoma: do they require a unique therapeutic approach?

Authors:  Kieron Dunleavy; Wyndham H Wilson
Journal:  Blood       Date:  2014-12-11       Impact factor: 22.113

5.  A predictive model for aggressive non-Hodgkin's lymphoma.

Authors: 
Journal:  N Engl J Med       Date:  1993-09-30       Impact factor: 91.245

6.  Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma.

Authors:  Kieron Dunleavy; Stefania Pittaluga; Lauren S Maeda; Ranjana Advani; Clara C Chen; Julie Hessler; Seth M Steinberg; Cliona Grant; George Wright; Gaurav Varma; Louis M Staudt; Elaine S Jaffe; Wyndham H Wilson
Journal:  N Engl J Med       Date:  2013-04-11       Impact factor: 91.245

7.  Primary Mediastinal (Thymic) Large B-Cell Lymphoma: Fidelity of Diagnosis Using WHO Criteria.

Authors:  Andrew Fairchild; Chad M McCall; Taofik Oyekunle; Donna Niedzwiecki; Colin Champ; Matthew McKinney; Chris R Kelsey
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2020-12-30

8.  Primary mediastinal large B-cell lymphoma.

Authors:  Anna Dabrowska-Iwanicka; Jan A Walewski
Journal:  Curr Hematol Malig Rep       Date:  2014-09       Impact factor: 3.952

Review 9.  Biology and therapy of primary mediastinal B-cell lymphoma: current status and future directions.

Authors:  Charlotte Lees; Colm Keane; Maher K Gandhi; Jay Gunawardana
Journal:  Br J Haematol       Date:  2019-02-10       Impact factor: 6.998

Review 10.  Primary Mediastinal B-Cell Lymphoma: A 2021 Update on Genetics, Diagnosis, and Novel Therapeutics.

Authors:  Zahoor Ahmed; Safa Saadat Afridi; Zeryab Shahid; Zarlakhta Zamani; Sana Rehman; Wajeeha Aiman; Maryam Khan; Muhammad Ayaz Mir; Farrukh T Awan; Faiz Anwer; Raheel Iftikhar
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2021-06-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.